ANXA2 and nonpapillary renal cell carcinoma: Moreover, high ANXA2 expression also indicated poor PFS in the ccRCC subgroup (P = 0.026, Supplementary Figure S1A) and the first-line therapy subgroup (P < 0.001, Supplementary Figure S1B).